Fully human antibodies for advanced immunotherapiesAnswering the increasing demand for novel fully human antibodies in immunotherapy, German biotech pioneer YUMAB GmbH accelerates drug discovery and development with a comprehensive and versatile technology … more ➔
Asthma needs to be targeted more specificallyUp to now, researchers believed that lung remodeling follows an autoimmune inflammation triggered by components of the extracellular matrix. In August, British scientists provided a more accurate view … more ➔
Innovative delivery: dual-chamber systemsAs the global demand for injectables grows, so does the demand for innovative delivery systems. For lyophilised forms, dual-chamber systems offer advantages. They have been on the market since the mid-1980s, … more ➔
Pioneers in the synbio revolutionIs synthetic biology on the cusp of unlocking the next industrial revolution? A major roadblock is the ability to synthesise DNA for R&D in ways that are both cheap and efficient. Established players … more ➔
Cutting time to market for high quality therapeuticsThe demand for the fast and robust development of manufacturing cell lines is ever growing, with an increasing number of therapeutic proteins in development. To fulfill these needs, Celonic engineered … more ➔
IMI fosters antibiotics research amidst Big Pharma pullbacksThe Innovative Medicines Initiative 2 (IMI2) has launched a new Antimicrobial Resistance Accelerator Programme following on the heels of its outgoing NewDrugs4BadBugs programme. more ➔
Experts discuss process intensificationRoughly 150 life science professionals met at the 5th Biotech Days to discuss the latest progress in bioprocess intensification. more ➔
Managing complexity to bring drugs to clinic fasterIntegrating the disparate stages of drug development is the most time and cost-efficient way of turning a promising candidate compound into a pharmaceutical product. A CDMO that offers coordinated end-to-end … more ➔
The future of agrochemistryOne of the world’s largest and most controversial mergers in the past few years was sealed in early June. German pharma and chemistry company Bayer has taken over US competitor Monsanto, forming the … more ➔
Closing the gap in haemophilia therapyAbout 25% of the people who suffer from haemophilia A have no therapeutic options, because their immune system forms antibodies against clotting products that can stop bleeding. Researchers and companies … more ➔
![Reference [1]?Schafer, S. et al. Nature 552, 110115 (2017)](https://european-biotechnology.com/wp-content/uploads/2024/04/EB_Autumn_2018_YUMAB-300x169.jpg "EB_Autumn_2018_YUMAB.jpg")
